Hennion & Walsh Asset Management, Inc. Macrogenics Inc Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 20, 2023	SELL	$4.82 - $7.24 $6,145 - $9,231	-1,275 Reduced 3.31%	37,207 $267,000
Q4 2022 Jan 12, 2023	BUY	$3.34 - $6.98 $16,249 - $33,957	4,865 Added 14.47%	38,482 $258,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $1,402 - $2,432	-466 Reduced 1.37%	33,617 $116,000
Q2 2022 Jul 19, 2022	SELL	$2.25 - $9.99 $1,140 - $5,064	-507 Reduced 1.47%	34,083 $101,000
Q1 2022 Apr 26, 2022	BUY	$8.12 - $16.9 $5,732 - $11,931	706 Added 2.08%	34,590 $305,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $33,729 - $46,385	2,120 Added 6.67%	33,884 $544,000
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $214,711 - $312,169	10,877 Added 52.08%	31,764 $665,000
Q2 2021 Aug 13, 2021	BUY	$20.49 - $35.63 $427,974 - $744,203	20,887 New	20,887 $561,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.